Efficacy of Target - Immunotherapy and XELOX Chemotherapy for Advanced HCC

NCT06818097 · clinicaltrials.gov ↗

COMPLETED

Status

68

Enrollment

OTHER

Sponsor class

Conditions

Advanced HCC
Systemic Therapy
Chemotherapy
Immunotherapy
Targeted Therapy
Efficacy and Safety

Interventions

DRUG: TKI
DRUG: anti PD-1
DRUG: XELOX chemotherapy

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University